- Quest Diagnostics reports a 12% revenue increase in Q1 2025 due to acquisitions and enterprise accounts.
- Wall Street's average target price suggests a 4.03% upside, rating the stock as "Outperform."
- GuruFocus estimates a potential downside of 9.78% based on the GF Value metric.
Quest Diagnostics Inc. (DGX, Financial) has showcased a robust start to 2025, with a notable 12% surge in Q1 revenues, totaling $2.65 billion. This growth was primarily fueled by strategic acquisitions and the expansion of enterprise accounts. Encouragingly, organic growth reached 2.5% by March, with adjusted earnings per share (EPS) recorded at $2.21. The management remains optimistic, reaffirming its 2025 revenue guidance in the range of $10.7 to $10.85 billion.
Wall Street Analysts Forecast
Wall Street analysts have weighed in with their projections for Quest Diagnostics Inc. (DGX, Financial), offering one-year price targets from 16 industry experts. The average target price is calculated at $180.78, with the highest estimate reaching $198.00 and the lowest at $160.00. This average target suggests a potential upside of 4.03% from the current stock price of $173.78. For a more detailed look, visit the Quest Diagnostics Inc (DGX) Forecast page.
In addition to price targets, the consensus from 20 brokerage firms positions Quest Diagnostics Inc. (DGX, Financial) with an average brokerage recommendation of 2.2, translating to an "Outperform" status. This rating is on a scale from 1 to 5, where 1 indicates a Strong Buy and 5 indicates a Sell.
Meanwhile, according to GuruFocus estimates, the GF Value for Quest Diagnostics Inc. (DGX, Financial) stands at $156.78, indicating a potential downside of 9.78% from the current market price of $173.78. The GF Value is a proprietary metric that assesses the fair value of a stock based on historical trading multiples, past business growth, and future business performance estimates. For further insights, visit the Quest Diagnostics Inc (DGX) Summary page.
